The ink was barely dry on Gilead Sciences, Inc.’s latest earnings report when the company announced another important milestone, the US Food and Drug Administration approval of Trodelvy (sacituzumab govitecan-hziy) based on survival data from the closely watched TROPiCS-02 trial in pretreated HR-positive/HER-negative metastatic breast cancer (HR+/HER2- mBC). The nod is the latest victory the drug maker has chalked up thanks to the large R&D program it also highlighted in its earnings report.
Gilead’s Trodelvy Basks In TROPiCS With FDA Breast Cancer Nod
Company Lays Out Development Strategy In Q4 Earnings
Gilead’s big push into oncology bore more fruit with the FDA approval of Trodelvy based on the TROPiCS-02 trial. More development catalysts lie ahead for 2023, company said in its earnings.
More from New Products
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.